Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Protocol ID
APEC1621F
Disease (Sub Disease)
All tumour types
Diagnosis Stage
Relapsed/refractory
Location
WA
Sponsor
National Cancer Institute (NCI)
Collaborators
Children's Oncology Group
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 21 Years
International registry ID's
NCT03213652
Back to Registry
Study Title NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Protocol ID APEC1621F
Disease (Sub Disease) All tumour types
Diagnosis Stage Relapsed/refractory
Location WA
Sponsor National Cancer Institute (NCI)
Collaborators Children's Oncology Group
Links https://clinicaltrials.gov/ct2/show/NCT03213652
Trial Status Open
Trial Open Date 17/04/2018
Sites Perth Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 12 Months to 21 Years
International registry ID's NCT03213652